DZ2395A1 - Composés nouveaux a noyau dibenzocycloheptène procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Composés nouveaux a noyau dibenzocycloheptène procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number
DZ2395A1
DZ2395A1 DZ980005A DZ980005A DZ2395A1 DZ 2395 A1 DZ2395 A1 DZ 2395A1 DZ 980005 A DZ980005 A DZ 980005A DZ 980005 A DZ980005 A DZ 980005A DZ 2395 A1 DZ2395 A1 DZ 2395A1
Authority
DZ
Algeria
Prior art keywords
dibenzocycloheptene
nucleus
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
DZ980005A
Other languages
English (en)
Inventor
William H Miller
William E Bondinell
Wen Fu Ku Thomas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2395A1 publication Critical patent/DZ2395A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ980005A 1997-01-08 1998-06-07 Composés nouveaux a noyau dibenzocycloheptène procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2395A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08

Publications (1)

Publication Number Publication Date
DZ2395A1 true DZ2395A1 (fr) 2003-06-04

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980005A DZ2395A1 (fr) 1997-01-08 1998-06-07 Composés nouveaux a noyau dibenzocycloheptène procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (30)

Country Link
US (2) US6069158A (fr)
EP (1) EP0977735B1 (fr)
JP (1) JP2001508067A (fr)
KR (1) KR20000069941A (fr)
CN (1) CN1249745A (fr)
AP (1) AP9901597A0 (fr)
AR (1) AR010873A1 (fr)
AT (1) ATE235467T1 (fr)
AU (1) AU729641B2 (fr)
BG (1) BG103548A (fr)
BR (1) BR9806852A (fr)
CA (1) CA2276738A1 (fr)
CO (1) CO4920232A1 (fr)
DE (1) DE69812602T2 (fr)
DZ (1) DZ2395A1 (fr)
EA (1) EA199900630A1 (fr)
ES (1) ES2196534T3 (fr)
HU (1) HUP0001945A3 (fr)
ID (1) ID23168A (fr)
IL (1) IL130760A0 (fr)
MA (1) MA26462A1 (fr)
NO (1) NO993350L (fr)
NZ (1) NZ336560A (fr)
OA (1) OA11076A (fr)
PE (1) PE44799A1 (fr)
PL (1) PL334499A1 (fr)
SK (1) SK92799A3 (fr)
TR (1) TR199901575T2 (fr)
WO (1) WO1998030542A1 (fr)
ZA (1) ZA9896B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304117A1 (fr) * 1997-09-04 1999-03-11 Dirk A. Heerding Antagonistes des recepteurs d'integrines
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
ATE542797T1 (de) 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
CA2358855A1 (fr) 1999-02-03 2000-08-10 Merck & Co., Inc. Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004513953A (ja) 2000-10-24 2004-05-13 メルク エンド カムパニー インコーポレーテッド ジベンズオキサゼピンαVインテグリン受容体アンタゴニスト
WO2002085405A2 (fr) 2001-04-24 2002-10-31 Merck Patent Gmbh POLYTHERAPIE A BASE D'AGENTS ANTIANGIOGENIQUES ET DE FACTEUR DE NECROSE TUMORALE TNF$g(a)
EP1443963B1 (fr) 2001-10-22 2014-05-21 The Scripps Research Institute Composes de ciblage d'anticorps
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
ES2671522T3 (es) * 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US8282943B2 (en) 2005-05-31 2012-10-09 Ralf Jochem Therapeutic composition for use in the prevention and treatment of bone metastases
WO2007048127A2 (fr) * 2005-10-20 2007-04-26 The Scripps Research Institute MARQUAGE DE PARTIES Fc POUR L'IMMUNOCOLORATION ET L'IMMUNOCIBLAGE
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(sarm) 및 이의 용도
EP2395992A2 (fr) 2009-02-10 2011-12-21 The Scripps Research Institute Vaccination programmée chimiquement
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CA2767409C (fr) 2009-07-24 2018-10-30 The Regents Of The University Of California Procedes et compositions destines a traiter et a prevenir des maladies associees a l'integrine ?v?5
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
PT910563E (pt) * 1995-06-29 2003-09-30 Smithkline Beecham Corp Antagonistas de receptores de integrina
JP2000502704A (ja) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
JP2002510328A (ja) * 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
CN1249745A (zh) 2000-04-05
ID23168A (id) 2000-03-23
KR20000069941A (ko) 2000-11-25
BG103548A (en) 2000-11-30
NO993350L (no) 1999-09-06
EA199900630A1 (ru) 2000-02-28
US6069158A (en) 2000-05-30
TR199901575T2 (xx) 1999-11-22
IL130760A0 (en) 2001-01-28
AU729641B2 (en) 2001-02-08
AU5912798A (en) 1998-08-03
JP2001508067A (ja) 2001-06-19
NO993350D0 (no) 1999-07-07
MA26462A1 (fr) 2004-12-20
CA2276738A1 (fr) 1998-07-16
OA11076A (en) 2003-03-13
EP0977735A1 (fr) 2000-02-09
ATE235467T1 (de) 2003-04-15
PE44799A1 (es) 1999-06-10
US6191304B1 (en) 2001-02-20
NZ336560A (en) 2000-11-24
PL334499A1 (en) 2000-02-28
DE69812602T2 (de) 2004-02-19
WO1998030542A1 (fr) 1998-07-16
CO4920232A1 (es) 2000-05-29
HUP0001945A3 (en) 2001-12-28
DE69812602D1 (de) 2003-04-30
HUP0001945A2 (hu) 2000-10-28
EP0977735B1 (fr) 2003-03-26
EP0977735A4 (fr) 2000-04-05
AP9901597A0 (en) 1999-09-30
BR9806852A (pt) 2001-08-07
ZA9896B (en) 1998-10-14
SK92799A3 (en) 1999-12-10
ES2196534T3 (es) 2003-12-16
AR010873A1 (es) 2000-07-12

Similar Documents

Publication Publication Date Title
DZ2395A1 (fr) Composés nouveaux a noyau dibenzocycloheptène procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
DZ2697A1 (fr) Composés azapolycycliques à noyau aryle condensé procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr) Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ3020A1 (fr) Acides oxamiques nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr) Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr) Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr) Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2751A1 (fr) Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.